9252. Tezosentan

Nomenclature

CAS number: 180384-57-0
N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-2-pyridinesulfonamide; 5-isopropylpyridine-2-sulfonic acid 6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-1H-tetrazol-5-ylpyridin-4-yl)pyrimidin-4-ylamide.
C27H27N9O6S; mol wt 605.62.
C 53.55%, H 4.49%, N 20.82%, O 15.85%, S 5.29%.

Description and references

Dual endothelin (ETA/ETB) receptor antagonist. Prepn: V. Breu et al., WO 9619459; eidem, US 6004965 (1996, 1999 both to Hoffmann-La Roche). Pharmacology and receptor binding: M. Clozel et al., J. Pharmacol. Exp. Ther. 290, 840 (1999). Clinical pharmacokinetics: J. Dingemanse et al., Br. J. Clin. Pharmacol. 53, 355 (2002). Clinical evaluation in advanced heart failure: C. Schalcher et al., Am. Heart J. 142, 340 (2001). LC-MS determn in plasma: P. L. M. van Giersbergen et al., J. Chromatogr. B 792, 369 (2003).

Chemical structure

Properties

White solid from acetonitrile, mp 198-200°.

Derivative

Sodium salt.

Nomenclature

CAS number: 180384-58-1
Ro-61-0612; Veletri (Actelion).
C27H25N9Na2O6S; mol wt 649.59.
C 49.92%, H 3.88%, N 19.41%, Na 7.08%, O 14.78%, S 4.94%.

Properties

White powder from sodium methylate. pKa1 4.4; pKa2 4.1. Sol in water.

Therapeutic Category

In treatment of congestive heart failure.

Keywords

Endothelin Receptor Antagonist